Amphotericin B dose optimization in children with malignant diseases

Chemotherapy

Volumn 53, Issue 2, 2007, Pages 142-147

  Nath, Christa E ^a,b   McLachlan, Andrew J ^b,c   Shaw, Peter J ^b   Coakley, John C ^a   Earl, John W ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Amphotericin B; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CYCLOSPORIN; HYDROCORTISONE;

ADOLESCENT; ADULT; ANALYTIC METHOD; ARTICLE; BODY WEIGHT; CHILD; CREATININE BLOOD LEVEL; DRUG TOLERANCE; HUMAN; INFANT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; STEADY STATE;

ADOLESCENT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; CREATININE; CYCLOSPORINE; DEOXYCHOLIC ACID; DRUG COMBINATIONS; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY DISEASES; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MYCOSES; NEOPLASMS; RISK FACTORS; UREA;

EID: 33847745805     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100013     Document Type: Article

References (13)

1. Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP, Strom BL: Risk factors for amphotericin B-associated nephrotoxicity. Am J Med 1989;87:547-552.
2. Nath CE, McLachlan AJ, Shaw PJ, Gunning R, Earl JW: Population pharmacokinetics of amphotericin B in children with malignant diseases. Br J Clin Pharmacol 2001;52:671-680.
3. Nath CE, Shaw PJ, Gunning R, McLachlan AJ, Earl JW: Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. Antimicrob Agents Chemother 1999;43:1417-1423.
4. P-Pharm Users Manual Version 1.4. Philadelphia, InnaPhase, 1996, chap 11, p 7.
5. Schumacher GE, Barr JT: Pharmacokinetics in drug therapy. Using population-based serum drug concentration cutoff values to predict toxicity: test performance and limitations compared with Bayesian interpretation. Clin Pharm 1990;9:788-796.
6. Schmeiser B: Approximations to the inverse cumulative normal function for use on hand calculators. Appl Stat 1979;28:175-176.
7. Carrillo-Munoz AJ, Quindos G, Tur C, Ruesga M, Alonso R, del Valle O, et al: Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and Fluconazole. Chemotherapy 2000;46:235-244.
8. Yee GC, Kennedy MS, Deeg HJ, Leonard TM, Thomas ED, Storb R: Cyclosporine-associated renal dysfunction in marrow transplant recipients. Transplant Proc 1985;17(suppl 1):196-201.
9. Kennedy MS, Deeg HJ, Siegel M, Crowley JJ, Storb R, Thomas ED: Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation 1983;35:211-215.
10. Heidemann HT, Gerkens JF, Anderson Spickard W, Jackson EK, Branch RA: Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983;75:476-481.
11. Garcia MT, Llorente MT, Minguez F, Prieto J: Influence of temperature and concentration on the postantifungal effect and the effects of sub-MIC concentrations of four antifungal agents on previously treated Candida species. Chemotherapy 2000;46:245-252.
12. Andes D: Minireview. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 2003;47:1179-1186.
13. Drutz DJ, Spickard A, Rogers DE, Koenig MG: Treatment of disseminated mycotic infections. Am J Med 1968;405-418.